Overview

A Multicenter, Single-Arm, Open-Label, Phase II Trial of Mosunetuzumab in Combination With Tislelizumab for r/r FL

Status:
NOT_YET_RECRUITING

Trial end date:
2027-07-30

Target enrollment:

Participant gender:

Summary

This is a multicenter, single-arm, open-label, investigator-initiated, phase II clinical trial designed to evaluate the feasibility, efficacy, and safety of Mosunetuzumab in combination with Tislelizumab in patients with relapsed/refractory follicular lymphoma (r/r FL).

Phase:

PHASE2

Details

Lead Sponsor:

Tianjin Medical University Cancer Institute and Hospital

Treatments:

tislelizumab